Management of non-small cell lung cancer in the era of personalized medicine

Research output: Contribution to journalReview article

Abstract

Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalInternational Journal of Biochemistry and Cell Biology
Volume78
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Precision Medicine
Angiogenesis Inhibitors
Chemotherapy
Non-Small Cell Lung Carcinoma
Surgery
Medicine
Tumors
Screening
Cells
Pharmaceutical Preparations
Therapeutics
Immunotherapy
Drug Therapy
Mutation
Survival
Neoplasms

Keywords

  • ALK
  • Early detection
  • EGFR
  • Immunotherapy
  • Non-small cell lung cancer (NSCLC)
  • Personalized medicine
  • Stereotactic ablative radiotherapy (SABR)
  • Video-assisted thoracoscopic surgery (VATS)

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

@article{7612d2e8756a46ce9d867fd5b46aea88,
title = "Management of non-small cell lung cancer in the era of personalized medicine",
abstract = "Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.",
keywords = "ALK, Early detection, EGFR, Immunotherapy, Non-small cell lung cancer (NSCLC), Personalized medicine, Stereotactic ablative radiotherapy (SABR), Video-assisted thoracoscopic surgery (VATS)",
author = "Gaetano Rocco and Alessandro Morabito and Alessandra Leone and Paolo Muto and Francesco Fiore and Alfredo Budillon",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.biocel.2016.07.011",
language = "English",
volume = "78",
pages = "173--179",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Management of non-small cell lung cancer in the era of personalized medicine

AU - Rocco, Gaetano

AU - Morabito, Alessandro

AU - Leone, Alessandra

AU - Muto, Paolo

AU - Fiore, Francesco

AU - Budillon, Alfredo

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.

AB - Despite major advances in the molecular definition of the disease, screening and therapy, non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival, depending on subtype and tumor stage. To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement. This short viewpoint describes the emerging strategies for the management of NSCLC, indicating how a personalized approach, characterized by a specific multidisciplinary involvement, implies a process that starts with early detection and includes surgery and systemic therapy.

KW - ALK

KW - Early detection

KW - EGFR

KW - Immunotherapy

KW - Non-small cell lung cancer (NSCLC)

KW - Personalized medicine

KW - Stereotactic ablative radiotherapy (SABR)

KW - Video-assisted thoracoscopic surgery (VATS)

UR - http://www.scopus.com/inward/record.url?scp=84981719332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981719332&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2016.07.011

DO - 10.1016/j.biocel.2016.07.011

M3 - Review article

AN - SCOPUS:84981719332

VL - 78

SP - 173

EP - 179

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

ER -